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This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.
Guidance

1.1
Omalizumab is not recommended for the treatment of severe persistent allergic asthma in children aged 6 to 11 years.
1.2
Children currently receiving omalizumab for the treatment of severe persistent allergic asthma should have the option to continue treatment until it is considered appropriate to stop. This decision should be made jointly by the clinician and the child and/or the child's parents or carers.
2
The technology
2.1 Omalizumab (Xolair, Novartis) is a monoclonal antibody that binds to immunoglobulin E (IgE). Initially omalizumab had marketing authorisation as an add-on therapy to improve control of asthma in adults and adolescents (12 years and older) with severe persistent allergic asthma. The marketing authorisation was extended in July 2009 to children aged 6 to 11 years who have severe persistent allergic asthma, a positive skin test or in-vitro reactivity to a perennial aeroallergen, frequent daytime symptoms or night-time awakenings, and multiple documented severe exacerbations of asthma despite daily high-dose inhaled corticosteroids plus a long-acting inhaled beta-2 agonist. The marketing authorisation
states that omalizumab treatment 'should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma'.
It also recommends that at 16 weeks after the start of therapy physicians should assess patients for the effectiveness of treatment before administering further injections, and that the decision to continue omalizumab should be based on whether a marked improvement in overall asthma control is seen.
2.2
The most common adverse events reported with omalizumab treatment in children aged under 12 years include headache, pyrexia and upper abdominal pain. Rare side effects in children and adults include parasitic infections and anaphylactic reactions. For the full details of adverse events and contraindications, see the summary of product characteristics (SPC).
2.3
Omalizumab is administered subcutaneously every 2 or 4 weeks. 
The manufacturer's submission
The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of omalizumab and a review of this submission by the Evidence Review Group (ERG; appendix B).
3.1
The manufacturer approached the decision problem by looking at children aged 6 to 11 years with severe allergic IgE-mediated asthma in accordance with the marketing authorisation.
Omalizumab as add-on therapy to standard care was compared with standard care alone. Standard care included high-dose inhaled corticosteroids, long-acting beta-2 agonists and, where appropriate, oral corticosteroids. The manufacturer included the following measures as health outcomes: clinically significant asthma exacerbations, clinically significant severe asthma exacerbations, emergency visits for asthma, use of oral corticosteroids, response to treatment as measured by the patients' and investigators' Global Evaluation of Treatment Effectiveness (GETE) 5-point scale, mortality, adverse effects of treatment and health-related quality of life. The outcome 'symptom-free days and nights' listed in the scope for this appraisal was not included; instead the manufacturer provided data relating to changes in morning, day, night-time and total symptom scores as an alternative endpoint.
3.2
In the manufacturer's submission, clinically significant exacerbations were defined as a worsening of asthma symptoms, as judged clinically by the investigator, which required doubling of the baseline dose of inhaled corticosteroid and/or treatment with rescue systemic (oral or intravenous) corticosteroids for at least 3 days. Clinically significant severe exacerbations were defined as exacerbations that required treatment with systemic corticosteroids and when the child had a peak expiratory flow rate or forced expiratory volume at 1 second (FEV1) of less than 60% of their personal best. The average utility score of omalizumab responders was estimated to be 0.779 and that of patients on standard care alone was assumed to be 0.669). However, as the PAQLQ administered as part of the IA-05 study did not show a significant difference between treatment groups, the manufacturer's submission assumed the lower value (0.669) for children in both groups until 12 years of age, at which point omalizumab responders were assigned the higher score (0.779). and £77,589 per QALY gained respectively. Probabilistic sensitivity analyses suggested that if the maximum acceptable cost for an additional QALY gained were either £20,000 or £30,000, omalizumab has a 0.0% probability of being cost effective.
3.21
Data on the cost effectiveness of omalizumab in the subgroup of children receiving maintenance oral corticosteroids were not presented in the manufacturer's submission because the small number of children receiving maintenance oral corticosteroids at baseline, all of whom were in the omalizumab plus standard care group, precluded a comparative analysis.
3.22
In general, the ERG considered the manufacturer's economic evaluation to be of good quality, meeting most of the requirements of the NICE reference case. The ERG considered the structure of the Markov model appropriate for the decision problem. The ERG noted the following concerns about the manufacturer's model.
The rates of response to treatment used in the model were derived from the IA-05 EUP subgroup at 52 weeks rather than at 16 weeks as specified in the marketing authorisation.
Exacerbation rates were not determined by the modified intention-to-treat analysis of the clinical trial but by comparing the rates observed in children who responded to omalizumab plus standard care -rather than children who were randomised to omalizumab plus standard care -with the rates observed in children in the standard care alone group for the last 28 weeks of the trial. No attempt was made to assess whether these two groups were similar and non-responders were omitted entirely from the analysis.
The manufacturer assumed a duration of treatment with omalizumab of 10 years. The ERG stated that no data had been submitted to support this assumption and suggested that in clinical practice the treatment duration would be shorter.
The manufacturer assumed that rates of exacerbations remained constant over the entire treatment duration for omalizumab plus standard care and over a lifetime for standard care alone. The ERG stated that during this period people would go through adolescence, which may have an impact on their asthma. It was therefore unclear whether this assumption was reasonable.
3.23
The ERG provided a revised cost-effectiveness result for the EUP hospitalisation subgroup that excluded the regression applied to the utility values in the model. The ICER was reduced from £65,911 to £65,884 per QALY gained. The ERG also carried out a series of sensitivity analyses of cost effectiveness in the EUP hospitalisation subgroup as the manufacturer had not presented a sensitivity analysis for this population. The main findings were similar to those in the base-case population.
3.24
The ERG also undertook exploratory analysis to identify the factors underlying the cost-effectiveness results in the population aged 6 to 11 years using the modelling that was used in NICE technology 
4.8
The Committee considered the costs associated with omalizumab which, in the model submitted by the manufacturer, were assumed to be constant over time. As the marketing authorisation specifies weight-based dosing, and because children are expected to grow and gain weight between ages 6 and 11, the Committee concluded that the assumption of constant cost could underestimate the true costs of treatment and therefore underestimate the ICER.
4.9
The Committee discussed the utility values used in the manufacturer's economic model. It was aware that the manufacturer had assumed no difference in utility values in day-today symptoms between omalizumab and standard care for children aged 6 to 11 years (0.699 for both standard care and omalizumab responders) but had assumed a difference in utility in day-to-day were absent from school on average 2 days less over a 52-week period than children randomised to standard care alone. The
Committee concluded that there was insufficient evidence to conclude that omalizumab would have a significant impact on school attendance, educational attainment or employment. The
Committee was also mindful that the impact of omalizumab on educational attainment and employment were outside NICE's reference case, which specifies that the costs and benefits of a technology should be considered from the perspective of the NHS and personal social services. The Committee then considered whether it was appropriate for the manufacturer to use different modelling assumptions regarding the utility values for day-to-day symptoms for children aged 6 to 11 years and people aged 12 years and older. Comments received during consultation suggested that children aged 6 to 11 years would be likely to receive the same benefits from omalizumab as people aged 12 years and older. The Committee noted that a carer for a child with asthma treated with omalizumab had observed significant improvements following treatment. The Committee noted that the ERG had undertaken an exploratory analysis for the hospitalisation subgroup in which a difference in utility between treatments was applied to all patients, including those aged 6 to 11 years, resulting in an ICER of £53,000 per QALY gained. The Committee concluded that the utility value used in the economic model for children aged 6 to 11 years may have underestimated the true benefit, but that an adjustment to the utility value would still lead to an ICER that exceeds the range usually considered a cost-effective use of NHS resources.
4.10
The Committee understood that a comment was provided during consultation noting that the Committee had failed to consider the low impact on the health budget of treating children with omalizumab, since relatively few children would need treatment.
The Committee noted that the NICE 'Guide to methods of technology appraisal' specifically states that the potential budget impact of the adoption of a new technology does not determine its decision.
4.11
The Committee considered the effect of the mortality rate associated with clinically significant severe exacerbations on the ICERs generated from the model. In the manufacturer's base case, the ICERs for the EUP and the hospitalisation subgroup were £91,200 per QALY gained and £65,900 per QALY gained respectively, assuming annual mortality rates in the UK from the study by Watson and colleagues (see section 3.13). The
Committee considered the ERG's exploratory analysis of the manufacturer's hospitalisation subgroup, in which the annual mortality rates reported in TA133 were applied in the current appraisal to children in the model as they reach 12 years of age.
The Committee noted that the ICERs decreased to £31,700 per QALY gained assuming an annual mortality rate of 3.109% and £34,000 per QALY gained assuming an annual mortality rate of 2.478%. The Committee heard from the clinical specialist that asthma-related mortality is rare and tends to occur in people with less severe but poorly controlled asthma, and that omalizumab therapy would not be considered appropriate for these people based on its marketing authorisation, because they would not fulfil the requirement for optimised therapy. Additionally, the Committee heard that the clinical specialist was not aware of any evidence suggesting an association between the number of exacerbations and mortality. The Committee was aware that using mortality rates fourfold higher than the modelled mortality rates would result in an 4.14 The Committee considered whether there were any other specific subgroups of people for whom the technology would be cost effective. The Committee noted that following consultation the manufacturer had presented cost-effectiveness estimates for patients who had experienced three or more exacerbations in the year before entering the study. It noted that the ICER for this subgroup of £82,600 per QALY gained was outside the range normally to be considered to be a cost-effective use of NHS resources. The Committee therefore concluded that omalizumab could not be recommended for this subgroup.
4.15
The Committee received comments during the consultation period about the role of omalizumab in research, including the comment that any future trial comparing oral corticosteroids with omalizumab may be unethical. The Committee appreciated that a design in which omalizumab as an add-on to standard care is compared with placebo in patients who are having frequent courses of oral corticosteroids, with oral corticosteroid use as an endpoint, would be better suited to UK clinical practice and provide information that is not available in the current evidence base.
4.16
The Committee considered whether its recommendation were associated with any potential issues related to the equality legislation and the requirement for fairness. The Committee understood that during the scoping period of this appraisal the issue was raised whether adherence to asthma treatment in children may be affected by parents or carers not providing regular medication because of socioeconomic or cultural reasons, rather than because of poor understanding. The Committee concluded that such factors would apply equally to all treatment options and therefore no changes to the recommendation could address this issue.
4.17
The Committee further considered comments received during consultation that not recommending omalizumab for children aged 6 to 11 years was unfair because omalizumab was recommended under specific circumstances for children aged 12 years and older in NICE technology appraisal 133. The Committee was aware of NICE's obligations to avoid age discrimination in the performance of its functions, which will apply when the Equality Act 2010 is brought into force. However these obligations are stated in the Act not to apply in relation to people who are younger than 18 years.
The Committee was also aware of the principles of 'Social value judgements' related to age, which state that patients should not be denied, or have restricted access to, NHS treatment simply because of their age. However, the Committee agreed that its decision on omalizumab for this age group was not made because of the age of the patients, but rather because omalizumab was not cost effective in this age group. This was because the avoidance of asthma-related death is a key driver for the ICER and children very rarely die from asthma. The Committee was aware that it needs to make a decision in each appraisal based on the evidence before it
and this is what it has done in this case. In addition, given the very high ICERs, the Committee considered the decision to be reasonable and rational, and in line with the Committee's role and the application of the cost-effectiveness criteria as described in the NICE methods for technology appraisal. The Committee had not identified any special factors which would require or justify making a positive recommendation despite the very high ICERs. However, the Committee noted that the fact that omalizumab for children aged 6 to 11 years was considered separately from omalizumab for people older than 12 years was a result of the timing of the regulatory process in the younger paediatric indication, which was outside NICE's control. The Committee concluded that it would be preferable to develop a single piece of guidance giving recommendations for all age groups, and that the most appropriate way to proceed would be to review the recommendations for all age groups together at the earliest opportunity.
Summary of the Appraisal Committee's key conclusions
TA201 (STA)
Appraisal title: Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years FAD section
Key conclusion
Reasons for key conclusion:
Omalizumab as an add-on to optimised standard care is more clinically effective than optimised standard care alone in terms of reducing clinically significant exacerbations for children aged 6 to 11 years with severe persistent allergic asthma only if they have experienced three or more clinically significant exacerbations in the previous year.
The most plausible ICER for the subgroup of patients who had experienced three or more clinically significant exacerbations in the year before entering the study was £82,600 per QALY gained.The Committee concluded that this ICER was substantially higher than those normally considered to be a cost-effective use of NHS resources.
1.1 4.4
4.14
Current practice
Clinical need of patients including the availability of alternative treatments
The main aim of treatment of asthma in children is to reduce the impact of the condition on children and their families, which includes attendance at accident and emergency departments, emergency GP visits, reduced attendance at school, limited social life and inability to undertake exercise. The impact on families may include anxiety, sleep deprivation and emotional and financial pressures.
The Committee noted that clinicians would wish to optimise therapy in an individual child before commencing omalizumab, which would normally be comparable to step 5 of the 'British guideline on the management of asthma. The Committee heard that children at step 5 of the 'British guideline on the management of asthma' require frequent or maintenance doses of oral corticosteroids.
4.3
The technology
Proposed benefits of the technology
How innovative is the technology in its potential to make a significant and substantial impact on health-related benefits?
The Committee noted that children and their families and carers value the possibility of a reduction in the number of exacerbations without the use of high-dose corticosteroids and are prepared to accept the inconvenience of attending specialist centres to have injections of omalizumab.
Omalizumab is a monoclonal antibody that binds to immunoglobulin E (IgE). Omalizumab has a marketing authorisation as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma.
2.1
What is the position of the treatment in the pathway of care for the condition?
The Committee heard that in clinical practice the population for whom omalizumab would be considered is more narrowly defined than in the ma:rketing authorisation and the IA-05 study, and would include children at step 5 of the 'British guideline on the management of asthma' requiring frequent or 4.3 maintenance doses of oral corticosteroids.
Adverse effects
The Committee was aware of the concerns of carers and clinicians regarding the long-term use of oral corticosteroids (the possible comparator at step 5 of the guidelines) because of side effects that include osteoporotic fractures and retarded growth. The Committee considered whether omalizumabmight be an alternative to oral corticosteroids, but concluded that there was no robust evidence showing a reduction in use of oral corticosteroids with omalizumab.
4.2, 4.4
Evidence for clinical effectiveness
Availability, nature and quality of evidence
One randomised controlled trial in children receiving omalizumab plus standard care or standard care alone. The manufacturer presented the results for subpopulations for children with more severe asthma to provide efficacy data aligned with the pre-existing EU marketing authorisation in adults and children aged 12 years and above (EUP). This was evaluated by the Committee.
The manufacturer also presented post-hoc efficacy analysis of one high-risk subgroup: the EUP hospitalisation subgroup. Following a request from the ERG, the manufacturer also provided analysis of EUP stratified by the number of exacerbations experienced in the previous year.
3. 3, 3.4, 4.4 3.7,3.8, 4.3, 4.5 Relevance to general clinical practice in the NHS
The Committee agreed that the trial population was not similar to the population of children who are likely to be considered for treatment with omalizumab, as in UK clinical practice these children would be treated with oral in addition to inhaled corticosteroids, rather than inhaled corticosteroids alone.
Based on the testimony of the clinical specialist, the Committee concluded that the EUP hospitalisation s subgroup was not clinically relevant in NHS clinical practice.
4.3
4.5
Uncertainties generated by the evidence
The Committee agreed that there were aspects of the IA-05 study that led to uncertainty, including the possibility that the EUP was not sufficiently powered to detect a difference in clinically significant exaberations with omalizumab.
4.4
Are there any clinically relevant subgroups for which there is evidence of differential effectiveness?
The Committee concluded that omalizumab as an addon to optimised standard care is more clinically effective than optimised standard care alone in terms of reducing exacerbations for children with severe persistent allergic asthma who have experienced three or more clinically significant exacerbations in the previous year.
Estimate of the size of the clinical effectiveness including strength of supporting evidence
The Committee agreed that analyses suggest a benefit in terms of clinically significant exacerbations only in children who had had three or more exacerbations in the year before the start of the study. The Committee concluded that omalizumab as an add-on to optimised standard therapy/standard care is more clinically effective than optimised standard therapy/standard care alone in terms of reducing exacerbations for children with severe persistent allergic asthma who have experienced three or more clinically significant exacerbations in the 4.4 previous year.
Evidence for cost effectiveness
Availability and nature of evidence The manufacturer's submission presented an economic analysis comparing omalizumab add-on therapy with standard care alone.
The Committee agreed that in general the the manufacturer's economic evaluation was of good quality.
3. 13-3.20 4.3
Uncertainties around and plausibility of assumptions and inputs in the economic model
The Committee accepted that the following factors were key uncertainties in the economic model: treatment duration asthma related mortality risk from clinically significant severe exacerbations basis for estimating omalizumab related drug costs.
4.6 -4.9, 4.11
Incorporation of health-related quality of life benefits and utility values
Have any potential significant and substantial health-related benefits been identified that were not included in the economic model, and how have they been considered?
The Committee discussed the utility values used in the manufacturer's economic mode and the comments received during consultation, which suggested that the utility values used in the manufacturer's economic model did not capture adequately the potential benefits of omalizumab The Committee concluded that the utility value used in the economic model for children aged 6 to 11 years may have underestimated the true benefit, but that an adjustment to the utility value would still lead to an ICER that exceeds the range usually considered a cost-effective use of NHS resources.
3.15 4.9
Are there specific groups of people for whom the technology is particularly cost-effective?
The Committee noted that following consultation on the Appraisal Consultation Document, the manufacturer had presented cost-effectiveness estimates for patients who had experienced three or more exacerbations in the year before entering the study. It noted that the ICER for this subgroup of £82,600 per QALY gained was outside the range normally to be considered to represent a cost effective use of NHS resources and therefore concluded that omalizumab could not be recommended for this subgroup.
4.14
What are the key drivers of cost effectiveness?
Assumptions about treatment duration and the mortality rate associated with clinically significant severe exacerbations were the key factor in the economic model.
The Committee was aware that using mortality rates fourfold higher than the observed mortality rates would result in an ICER of £43,100 per QALY gained, and concluded that making such assumption would be inappropriate in the light of the evidence.
4.11
Most likely cost-effectiveness estimate (given as an ICER)
The manufacturer's ICERs were £91,200 and £65,900 per QALY gained for the EUP and for the hospitalisation subgroup,respectively, based on a 10-year treatment duration. For a more plausible treatment duration of 5 years the ICERs would be higher. The ERG'S exploratory analysis of the hospitalisation subgroup, in which it was assumed that there was a difference in utility values between treatments for all patients, including those aged 6 to 11 years, resulted in an ICER of £53,000 per QALYgained. The Committee concluded that such ICERs were substantially higher than those normally considered to be an acceptable use of NHS resources and concluded that omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years could not be recommended as a cost-4.11 and 4.13 effective use of NHS resources. Th The Committee further considered comments received during consultation that not recommending omalizumab for children aged 6 to 11 years was unfair because omalizumab was recommended under specific circumstances for children aged 12 years and older as a result of the recommendation in NICE technology appraisal 133. The Committee was aware of NICE's obligations to avoid age discrimination in the performance of its functions, which will apply when the Equality Act 2010 is brought into force. However these obligations are stated in the Act not to apply in relation to people who are younger than 18 years. The Committee was also aware of the principles of 'Social value judgements related to age, which state that patients should not be denied, or have restricted access to NHS treatment simply because of their age. However, the Committee agreed that its decision on omalizumab for this age group was not made because of the age of the patients, but rather because omalizumab was not costeffective in this age group. The Committee noted that the fact that omalizumab for children aged 6 to 11 years was considered separately from omalizumab for people older than 12 years was a result of the timing of the regulatory process in the younger paediatric indication, which was outside NICE's control. The Committee concluded that it would be preferable to develop a single piece of guidance giving recommendations for all age groups, and that the most appropriate way to proceed would be to review the recommendations for all age groups together at the earliest opportunity. Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal. 
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